替拉万星对由达托霉素和耐甲氧西林金黄色葡萄球菌菌株引起的实验性主动脉瓣心内膜炎具有活性。
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
作者信息
Abdelhady Wessam, Bayer Arnold S, Gonzales Rachelle, Li Liang, Xiong Yan Q
机构信息
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Division of Infectious Diseases, LAC Harbor-UCLA Medical Center, Torrance, California, USA.
出版信息
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01877-16. Print 2017 Feb.
Abstract
We compared the efficacy of telavancin (TLV) and daptomycin (DAP) in an experimental rabbit endocarditis model caused by two clinically derived daptomycin-resistant (DAP) methicillin-resistant Staphylococcus aureus (MRSA) strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative compared to those with the untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAP MRSA isolates in this invasive endovascular infection model.
摘要
我们比较了替考拉宁（TLV）和达托霉素（DAP）在由两株临床分离的对达托霉素耐药（DAP）的耐甲氧西林金黄色葡萄球菌（MRSA）菌株引起的实验性兔心内膜炎模型中的疗效。与未治疗的对照组或接受达托霉素治疗的动物相比，替考拉宁治疗显著降低了所有靶组织中的MRSA密度，并增加了这些器官培养阴性的百分比。这些结果表明，在这种侵袭性血管内感染模型中，替考拉宁对DAP MRSA分离株具有强大的体内疗效。
相似文献
1
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01877-16. Print 2017 Feb.
2
Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2012 Nov;56(11):5528-33. doi: 10.1128/AAC.00922-12. Epub 2012 Aug 13.
3
Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
J Antimicrob Chemother. 2016 Oct;71(10):2890-4. doi: 10.1093/jac/dkw249. Epub 2016 Jun 26.
4
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").
Antimicrob Agents Chemother. 2010 Aug;54(8):3161-9. doi: 10.1128/AAC.00487-10. Epub 2010 Jun 14.
5
Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Antimicrob Agents Chemother. 2015 Sep;59(9):5529-34. doi: 10.1128/AAC.00773-15. Epub 2015 Jun 29.
6
In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis.
Int J Infect Dis. 2013 Nov;17(11):e1076-7. doi: 10.1016/j.ijid.2013.02.019. Epub 2013 Apr 9.
7
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2012 Feb;56(2):955-9. doi: 10.1128/AAC.05849-11. Epub 2011 Nov 28.
8
The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02633-17. Print 2018 Jun.
9
Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
Antimicrob Agents Chemother. 2010 Aug;54(8):3079-85. doi: 10.1128/AAC.00122-10. Epub 2010 May 24.
10
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0050821. doi: 10.1128/AAC.00508-21.
引用本文的文献
1
Rapid activity of telavancin against and protection against inhalation anthrax infection in the rabbit model.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0011224. doi: 10.1128/aac.00112-24. Epub 2024 Jun 18.
2
The Purine Biosynthesis Repressor, PurR, Contributes to Vancomycin Susceptibility of Methicillin-resistant Staphylococcus aureus in Experimental Endocarditis.
J Infect Dis. 2024 Jun 14;229(6):1648-1657. doi: 10.1093/infdis/jiad577.
3
Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Infection: a Novel Combination Therapy.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.02039-20.
4
Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.
Clin Microbiol Rev. 2019 Feb 13;32(2). doi: 10.1128/CMR.00041-18. Print 2019 Mar 20.
5
The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Bacteriolysis.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02291-18. Print 2019 Apr.
6
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
本文引用的文献
1
Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
J Antimicrob Chemother. 2016 Oct;71(10):2890-4. doi: 10.1093/jac/dkw249. Epub 2016 Jun 26.
2
Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S58-68. doi: 10.1093/cid/civ534.
3
Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.
Antimicrob Agents Chemother. 2014 Sep;58(9):5547-51. doi: 10.1128/AAC.03172-14. Epub 2014 Jul 14.
4
Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant Staphylococcus aureus.
J Infect Dis. 2014 Apr 15;209(8):1231-40. doi: 10.1093/infdis/jiu007. Epub 2014 Jan 7.
5
Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2012 Nov;56(11):5528-33. doi: 10.1128/AAC.00922-12. Epub 2012 Aug 13.
6
Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Dec;55(12):5631-9. doi: 10.1128/AAC.05251-11. Epub 2011 Oct 3.
7
In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):275-9. doi: 10.1016/j.diagmicrobio.2010.09.017.
8
Waves of resistance: Staphylococcus aureus in the antibiotic era.
Nat Rev Microbiol. 2009 Sep;7(9):629-41. doi: 10.1038/nrmicro2200.
9
Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
Antimicrob Agents Chemother. 2009 Apr;53(4):1463-7. doi: 10.1128/AAC.01307-08. Epub 2009 Jan 26.
10
Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model.
J Infect Dis. 2009 Jan 15;199(2):201-8. doi: 10.1086/595738.
Zotero 插件